The sleep economy is 'having a moment', says medical equipment firm Resmed
Carlos Nunez, Chief Medical Officer of Resmed takes about the opportunities and challenges in the sleep economy with CNBC's Martin Soong. He joins 'Squawk Box Asia' on the sidelines of the World Sl...
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
Spot Outliers Like ResMed Early with Money Flows
ResMed, Inc. (RMD) shares up almost 3,142% since first Big Money outlier signal in 2000.
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed: Cornering The Market In Sleep Solutions
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D...
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations O...
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago.
ResMed slightly beats quarterly profit estimates on sleep devices demand
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett ...
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $1.88 per share a year ago.
ResMed Gains 37.8% in a Year: What's Driving the Stock?
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why ResMed (RMD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Related Companies